Bibert Pharmaceutical HDAC/PI3K dual-target anti-cancer class 1 new drugs were approved clinically

Screenshot source: CDE official website HDAC (histogen deacetylase) controls cell survival, proliferation, angiogenesty, inflammation and immunity, and plays an important role in cell signaling.
because of the basic role of HADC in gene expression and its different effects on histoproteins and non-heroproteins, it has been considered an ideal target for the treatment of malignant tumors such as lymphoma.
PI3K is phosphatidyl inositol-3-kinase.
PI3K/AKT/mTOR is one of the most important signaling path paths in cells and plays an important role in regulating cell growth, movement, survival, metabolism and angiogenesis.
study found a significant correlation between the over-activity of PI3K signaling paths and tumor progression, the increase of tumor microvascular density, and the trending and invasive enhancement of cancer cells.
according to Bibet Pharmaceuticals' official website, BEBT-908 is the company's own research and development of a dual-target anti-cancer drug targeting both HDAC and PI3K.
BEBT-908 is able to selectively inhibit the core target of synergetic tumor cell messengers, disrupt tumor cell messenger networks, significantly inhibit lymphoma and myeloma growth or cause tumors to subside.
public information shows that BEBT-908 has been approved in China for the diffuse large B cell lymphoma, recurring difficult to treat lymphoma, multiple myeloma and chronic lymphocytic leukemia and other clinical studies.
is currently under way in an open, multi-center Phase 2 clinical study to assess the effectiveness and safety of BEBT-908 treatment for relapsed or incurable large B-cell lymphoma.
phase 1 clinical trial showed that BEBT-908 was safe and effective in treating non-Hodgkin's lymphoma.
this time, BEBT-908's approved clinical study is aimed at a new adaptation, the development of treatments for recurring or incurable external T-cell lymphoma and skin T-cell lymphoma.
T-cell lymphoma is a rare and fast-growing non-Hodgkin's lymphoma developed by T-cells, which spread rapidly throughout the body, causing the disease to become difficult to treat.
T-cell lymphoma is a rare non-Hodgkin's lymphoma caused by T-lymphocyte cancer, which usually migrates to the skin.
this can cause different types of lesions on the patient's skin, which may initially be red and swollen, but as the disease progresses it may turn into bulging plaques and tumors, with a medium survival of only 2.5 years in advanced patients.
, these patients still need new treatment options.
: The Drug Review Center of the State Drug Administration of China. Retrieved Dec 3,2020, from s2.
From Source: Supplied